Pages

Showing posts with label cancer - cervical. Show all posts
Showing posts with label cancer - cervical. Show all posts

Friday, 2 October 2009

HPV vaccine for Cervical Cancer, in the clear


HPV vaccine in the clear

NHS ChoicesOct 02, 2009 17:35:00 GMT Share


A pathologist has confirmed that the human papilloma virus (HPV) vaccine did not cause the death of Natalie Morton, the schoolgirl from Coventry.
Early media speculation suggested the anti-cancer jab could be responsible, but a post-mortem has found that she died from a large malignant tumour of the heart and lungs.
Dr Caron Grainger, joint director of public health for NHS Coventry and Coventry City Council, said, “The pathologist has confirmed today at the opening of the inquest into the death of Natalie Morton that she died from a large malignant tumour of unknown origin in the heart and lungs. There is no indication that the HPV vaccine, which she had received shortly before her death, was a contributing factor to the death, which could have arisen at any point”.
“We hope that this news will reassure parents that the vaccine is safe and that they should continue to encourage their daughters to be protected against cervical cancer. The HPV vaccination programme will continue as planned in the city from Monday.”


Why was a link made between the HPV vaccine and the girl’s death?

No link should ever have been made. However, the girl died on the same day as receiving her vaccination and this led to associations being drawn between the jab and her death.
This happens largely through misinterpretation of probabilities. Unfortunately, young people do die suddenly of natural causes. Although such events are rare, they are statistically much more common than fatal reactions to routine medical treatments.


Do people ever have severe adverse reactions to vaccinations?

They do, but it is much less common than many people think.
In very rare cases, it is possible for someone who is vaccinated to experience an allergic reaction, known as an anaphylactic reaction. These are extraordinarily rare, with a recent study showing that only one anaphylactic reaction is reported in about a million immunisations.
Moreover, most anaphylactic reactions to vaccines do not result in death. According to data from the Office for National Statistics, there has not been a single recorded death due to anaphylactic shock following a vaccination for at least 10 years. This covers all recorded incidents between 1997 and 2007, the last year for which data are available.


What are the benefits of the HPV jab?

It’s been calculated that the UK HPV vaccination programme will ultimately save 400 lives a year. Around 3,000 women a year are currently diagnosed with cervical cancer, and the disease kills more than 1,000 women a year in the UK.
Half of all sexually active women will be infected by a strain of HPV in their lifetime. These infections cause more than 99% of cervical cancer cases and a range of other cancers.
The HPV vaccine protects against two types of HPV: strains 16 and 18. Together these cause around 70% of cervical cancers.


Have any side effects been reported?

Yes. All drugs have side effects and the HPV vaccine is no different.
Very common side effects include:
  • pain or discomfort at the injection site,
  • redness or swelling at the injection site,
  • headache,
  • aching muscles, muscle tenderness or weakness (not caused by exercise), and
  • tiredness.
Common side effects include:
  • gastrointestinal symptoms including nausea, vomiting, diarrhoea and abdominal pain,
  • itching, red skin rash, hives (urticaria),
  • joint pain, and
  • fever (≥38°C).
Uncommon side effects (occurring in less than one per 100 but more than one per 1,000 doses of vaccine):
  • upper respiratory tract infection (infection of the nose, throat or trachea),
  • dizziness, and
  • other injection site reactions such as hard lump, tingling or numbness.
For more on the vaccine’s known side effects go to Health A-Z: side effects.


Does the vaccine have a good safety record?

The vaccine’s safety record is excellent and it has passed the rigorous safety tests needed for it to be used in the UK and other European countries.
It underwent safety testing as part of the licensing process, with over 70,000 doses used in clinical trials here before a licence was granted (it’s now licensed in more than 90 other countries).
In total, more than 1.4 million doses of the vaccine have since been given in Britain, and millions more worldwide.


Who should have the vaccine?

The HPV vaccine is being offered to all girls aged 12-13 as part of a national vaccination programme that aims to cut deaths and serious illness from cervical cancer. The vaccination programme began in September 2008. By 2011, all girls under 18 in Britain will have been offered the jab. The vaccine is given in three injections over six months. A catch-up programme also started in September 2008 and offers the vaccine to other older girls up to the age of 18.


How does the vaccine work?

Virtually all cases of cervical cancer are caused by a virus called human papilloma virus (HPV), which is passed on during sex (although sexual intercourse isn’t always necessary to pass on the virus).
The vaccine, Cervarix, which is used in the NHS national programme protects against two types of HPV, strains 16 and 18, which together cause around 70% of cervical cancers.


What is HPV?

HPV is a virus that infects the deepest layer of the skin or genital surfaces. There are over 100 different types of HPV, 13 of which are known to cause cervical cancer. The others are harmless or cause genital warts. The virus is transmitted through sexual contact and is very common, with over half of all women becoming infected at some point in their lifetime.


How does HPV cause cancer?

Most HPV infections clear up by themselves, but in some people the infection can last a long time.
HPV infects the cells of the surface of the cervix (the neck of the womb), where it can stay for years without anyone knowing.
HPV can damage these cells, causing changes in their appearance. Over time, these changes can develop into cervical cancer.


Will the cervical cancer programme be suspended?

No. There are no plans to suspend the vaccination programme.
As with any vaccine, Cervarix is associated with side effects, but overall this is a well tested vaccine that’s been introduced to tackle a serious health problem.
The MHRA has reviewed all reported side effects related to Cervarix and concluded there is no evidence to suggest that the vaccine carries any long-term side effects.
The independent Expert Advisory Group of the Commission on Human Medicines has reviewed the data and endorses the MHRA’s view that no new or serious risks have been identified and the balance of risks and benefits remains overwhelmingly favourable.


Should I let my daughter have the cervical cancer jab?

Yes. The established risks of getting cervical cancer are far, far greater than any risk from the HPV vaccine.

Saturday, 26 September 2009

Vaccine could wipe out cervical cancer within 50 years


G has just had the vaccine for Cervical cancer (14-15 year old girls)
25/09/2009
The Independent
By: Presswatch
Vaccine could wipe out cervical cancer within 50 years
Cervical cancer could be eradicated within five decades by screening and vaccination programmes, a leading expert said yesterday. Professor Jack Cuzick called on European governments to spearhead a concerted effort to make the disease disappear. Currently vaccines exist that can protect women against two strains of the human papilloma virus (HPV) that causes cervical cancer. These alone had the potential to eradicate three quarters of cancers, said Prof Cuzick, from the Cancer Research UK Centre for Epidemiology in London.

Friday, 21 September 2007

Many under-16s carry cancer virus

reposted from: http://news.bbc.co.uk/1/hi/health/7002887.stm

Many under-16s carry cancer virus
Cervical smear showing HPV infection
HPV infection is the leading cause of cervical cancer
At least one in 10 girls in England is infected by the age of 16 with a virus which can cause cervical cancer, research suggests.

A study by the Health Protection Agency (HPA) found many teenagers are infected with at least one strain of the human papillomavirus (HPV).

The researchers found the risk of infection is "substantial" by the age of just 14.

A vaccination programme for girls as young as 12 is set to begin next year.

The plans have attracted criticism by those who claim the programme will encourage promiscuity, but advocates have argued that it is necessary to start early to maximise the impact on public health.

HPV is responsible for most cases of cervical cancer, which kills more than 1,000 woman a year in the UK.

The HPA researchers tested blood samples from 1,483 females aged 10 to 29 for signs of HPV infection.

The results, published in the British Journal of Cancer, showed that by the age of 18 around one in five females show signs of infection, and by the age of 24 the figure climbs to around 40%.

Not compulsory

Professor Pat Troop, HPA chief executive, said: "This study is a valuable addition to our understanding of HPV infection in women in England and should contribute to effective policies to prevent genital warts and cervical cancer.

"With the government's recent announcement of the possible introduction of HPV vaccination, such research will help us and other public health experts to determine the impact of HPV vaccination."

The Department of Health, acting on a recommendation from a committee of experts, announced plans in June to start a HPV vaccination programme next year.

It is likely that girls aged 12 to 13 will be offered the vaccine in three doses over a six-month period. There will be no compulsion.

At present, there are two vaccines designed to be used in a vaccination programme.

Gardasil, made by Merck and Sanofi Pasteur, has already been approved in many countries, while Cervarix, mae by GlaxoSmithKline, is expected to be launched in Europe later this year.

Latest data on Gardasil shows it protects against a total of 14 different strains of HPV, all of which can cause pre-cancerous lesions.

It provides almost complete protection against HPV types 16 and 18 - which together cause 75% of cervical cancer worldwide.

Sex education

Juliet Hillier, of the sexual health charity Brook, said of the latest research: "Statistics like this demonstrate a real need to improve education and prevention programmes which target young people.

"The government must urgently implement a vaccination programme for girls and boys before they become sexually active and ensure resource is available to do so."

Norman Wells, from the Family Education Trust, said: "These disturbing figures highlight the failure of sex education programmes which tell children that there is nothing wrong with sex at any age so long as they use a condom."

The HPA also released a "modelling" study showing that a vaccination programme would be a cost-effective use of NHS resources if the jab protected girls against cervical cancer for at least 20 years.

Its research showed that up to 70% of cases of cervical cancer and 95% of cases of genital warts in men and women could be prevented by the jab.